Publications by authors named "R N Thareja"

The global prevalence of obesity currently exceeds 1 billion people and is accompanied by an increase in the aging population. Obesity and aging share many hallmarks and are leading risk factors for cardiometabolic disease and premature death. Current anti-obesity and pro-longevity pharmacotherapies are limited by side effects, warranting the development of novel therapies.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is the third most common cancer worldwide, acting as a significant public health problem. 5-Fluorouracil (5-FU) is a key chemotherapy for various types of cancer, due to its broad anticancer activity. However, the emergence of drug resistance is a considerable limitation in the clinical application of 5-FU.

View Article and Find Full Text PDF

Coronary stents have saved millions of lives in the last three decades by treating atherosclerosis especially, by preventing plaque protrusion and subsequent aneurysms. They attenuate the vascular SMC proliferation and promote reconstruction of the endothelial bed to ensure superior revascularization. With the evolution of modern stent types, nanotechnology has become an integral part of stent technology.

View Article and Find Full Text PDF

Nitric oxide synthase 3 (NOS3) eluting polyvinyl alcohol-based hydrogels have a large potential in medical applications and device coatings. NOS3 promotes nitric oxide and nitrate production and can effectively be delivered using insect cell viruses, termed baculoviruses. Nitric oxide is known for regulating cell proliferation, promoting blood vessel vasodilation, and inhibiting bacterial growth.

View Article and Find Full Text PDF
Article Synopsis
  • RNA interference (RNAi) using small interfering RNA (siRNA) shows promise for treating genetic disorders but faces significant delivery challenges due to various barriers.
  • Strategies to enhance siRNA delivery include chemical modifications, bioconjugation with ligands, and nanotechnology-based systems like liposomes and nanoparticles.
  • Despite the established mechanism of siRNA as a gene silencer, effective therapeutic products remain limited, and there's an urgent need for improved delivery systems to target specific sites for treating diseases early on.
View Article and Find Full Text PDF